Upgrade to SI Premium - Free Trial

BMO Capital Reiterates Outperform Rating on Pfizer (PFE) following Ph2 data

March 9, 2026 11:51 AM
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $30.00 price target on Pfizer (NYSE: PFE)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments